Oral Compositions Comprising Zinc Citrate and/or Tocopherol Agents

Abstract

Methods and oral compositions for reducing one or more of plaque, tartar, caries, dentinal sensitivity, malodor, and/or inflammation are provided. The composition comprise an active ingredient that comprises a zinc salt.

1 . A method of treating an oral surface having dental sensitivity comprising contacting the oral surface with an oral composition comprising an active ingredient comprising a zinc citrate agent and a potassium salt.  
   
   
       2 . A method according to  claim 1 , wherein the potassium salt is a potassium citrate agent.  
   
   
       3 . The method according to  claim 1 , wherein the zinc citrate agent comprises a compound having a general formula of Zn 3 (C 6 H 5 O 7 ) 2 .  
   
   
       4 . The method according to  claim 2 , wherein the potassium citrate agent comprises a compound having a general formula of K 3 C 6 H 5 O 7 .  
   
   
       5 . The method according to  claim 1 , wherein the active ingredient further comprises a compound chosen from potassium tartrate, potassium chloride, potassium sulfate, potassium nitrate, sodium nitrate, sodium citrate or mixtures thereof.  
   
   
       6 . The method according to  claim 1 , wherein a ratio of the zinc citrate agent to the potassium salt is about 0.5:1 to about 1:0.5.  
   
   
       7 . The method according to  claim 1 , wherein the zinc citrate agent is present in an amount of about 0.001% to about 5% by weight of the oral composition and the potassium salt is present in an amount of about 0.001% to about 10% by weight of the oral composition.  
   
   
       8 . The method according to  claim 1 , wherein the oral composition further comprises a copolymer of maleic anhydride and polyvinyl methyl ether.  
   
   
       9 . The method according to  claim 1 , wherein the oral composition further comprises a polyphosphate compound.  
   
   
       10 . The method according to  claim 1 , wherein the oral composition further comprises a copolymer of maleic anhydride and polyvinyl methyl ether and a polyphosphate agent.  
   
   
       11 . A method of reducing astringency comprising contacting the oral surface with an oral composition comprising an active ingredient comprising a zinc citrate agent and a potassium salt.  
   
   
       12 . A method of reducing formation of plaque or tartar, caries or malodor comprising contacting the oral surface with an oral composition comprising an active ingredient comprising a zinc citrate agent and a potassium salt.  
   
   
       13 . The method according to  claim 1 , wherein the oral composition further comprises a non-ionic halogenated diphenyl ether.  
   
   
       14 . The method according to  claim 1 , wherein the oral composition further comprises a tocopherol agent.  
   
   
       15 . The method according to  claim 1 , wherein the oral composition has a pH of about 6 to about 10.  
   
   
       16 . The method according to  claim 1 , wherein the oral composition is in a form of a mouthrinse, a dentifrice, a confectionary, a medicament, or a film.  
   
   
       17 . A method of treating inflammation in an oral tissue comprising: contacting the inflamed oral tissue with an oral composition comprising an active ingredient comprising a zinc citrate agent and a tocopherol agent.  
   
   
       18 . The method according to  claim 17 , wherein the tocopherol agent comprises a compound chosen from tocol (2-methyl-2-(4,8,12-trimethyltridecyl)-6-chromanol), α-tocopherol ((+)-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol), β-tocopherol ((+)-2,5,8-trimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol), γ-tocopherol ((+)-2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol), δ-tocopherol ((+)-8-methyl-2-(4,8,12-trimethyltridecyl)-6-chromanol), β-tocotrienol (2,5,7,8-tetramethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-6-chromanol), β-tocotrienol (2,5,8-trimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-6-chromanol) or derivatives or mixtures thereof.  
   
   
       19 . The method according to  claim 17 , wherein the tocopherol agent comprises α-tocopherol ((+)-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol), and γ-tocopherol ((+)-2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol).  
   
   
       20 . The method according to  claim 17 , wherein the tocopherol agent is present in an amount of about 0.001% to about 5%.  
   
   
       21 . An anti-plaque and desensitizing oral composition comprising: 
 an active ingredient comprising a zinc citrate agent and a potassium citrate agent; and    a copolymer of maleic anhydride and polyvinyl methyl ether and a polyphosphate.    
   
   
       22 . The composition according to  claim 21 , wherein the zinc citrate agent comprises a compound having a general nominal formula of Zn 3 (C 6 H 5 O 7 ) 2 .  
   
   
       23 . The composition according to  claim 21 , wherein the potassium citrate agent comprises a compound having a general nominal formula of K 3 C 6 H 5 O 7 .  
   
   
       24 . The composition according to  claim 21 , wherein the active ingredient further comprises a compound chosen from potassium tartrate, potassium chloride, potassium sulfate, potassium nitrate, sodium nitrate, sodium citrate or mixtures thereof.  
   
   
       25 . The composition according to  claim 21 , wherein a ratio of the zinc citrate agent to the potassium citrate agent is about 0.5:1 to about 1:0.5.  
   
   
       26 . The composition according to  claim 21 , wherein the zinc citrate agent is present in an amount of about 0.001% to about 5% by weight of the oral composition and the potassium citrate agent is present in an amount of about 0.001% to about 10% by weight of the oral composition.  
   
   
       27 . The composition according to  claim 21 , wherein the oral composition further comprises a non-ionic halogenated diphenyl ether.  
   
   
       28 . The composition according to  claim 21 , wherein the oral composition is in a form of a mouth rinse, a dentifrice, a confectionary, a medicament, or a film.  
   
   
       29 . An oral composition comprising: 
 an oral care active ingredient comprising a zinc citrate agent and a tocopherol agent, wherein the tocopherol agent comprises at least one compound chosen from tocol (2-methyl-2-(4,8,12-trimethyltridecyl)-6-chromanol), α-tocopherol ((+)-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol), β-tocopherol ((+)-2,5,8-trimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol), γ-tocopherol ((+)-2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol), δ-tocopherol ((+)-8-methyl-2-(4,8,12-trimethyltridecyl)-6-chromanol), α-tocotrienol (2,5,7,8-tetramethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-6-chromanol), β-tocotrienol (2,5,8-trimethyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-6-chromanol) or derivatives or mixtures thereof.    
   
   
       30 . The composition according to  claim 29 , wherein the tocopherol agent comprises α-tocopherol ((+)-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol), and γ-tocopherol ((+)-2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol).  
   
   
       31 . The composition according to  claim 29 , wherein the tocopherol agent is present in an amount of about 0.001% to about 5%.  
   
   
       32 . The composition according to  claim 29 , wherein the zinc citrate agent is present in an amount of about 0.001% to about 5% and the tocopherol agent is present in an amount of about 0.001% to about 5% by weight of the composition.  
   
   
       33 . The composition according to  claim 29 , wherein the composition further comprises a copolymer of maleic anhydride and polyvinyl methyl ether and a polyphosphate agent for reducing astringency of the zinc citrate agent.  
   
   
       34 . The composition according to  claim 29 , wherein the composition further comprises a non-ionic halogenated diphenyl ether.  
   
   
       35 . An oral composition comprising a zinc salt, a linear polyphosphate salt having an average chain length of 3 or less, and at least one of a potassium salt or a vitamin.  
   
   
       36 . The oral composition according to  claim 35 , wherein the linear polyphosphate salt is a pyrophosphate.  
   
   
       37 . The oral composition according to  claim 36 , wherein the linear polyphosphate salt is a tripolyphosphate.